Medclair (MCLR) Q4 2024 earnings summary

Executive summary

• Achieved strong order intake growth of 26% year-over-year to 62.3 MSEK, with Q4 order intake up 29% compared to Q4 2023.

• Net sales for 2024 were 35.4 MSEK, a decrease from 39.9 MSEK in 2023, but underlying demand remains robust.

• Net income improved to 1.5 MSEK for 2024 from -2.8 MSEK in 2023; Q4 net income was 0.6 MSEK versus -1.9 MSEK in Q4 2023.

• Divestment of Spintso AB completed, making Medclair a focused green-tech company.

• Medclair's technology enabled customers to eliminate 84,000 tons of CO2e in 2024.

Financial highlights

• Q4 2024 net sales: 7.6 MSEK (Q4 2023: 11.9 MSEK); full-year 2024: 35.4 MSEK (2023: 39.9 MSEK).

• EBITDA for Q4: 2.0 MSEK (Q4 2023: 0.0 MSEK); full-year EBITDA: 2.0 MSEK (2023: 3.8 MSEK).

• Net income for Q4: 0.6 MSEK (Q4 2023: -1.9 MSEK); full-year: 1.5 MSEK (2023: -2.8 MSEK).

• EPS for 2024: 0.02 SEK (2023: -0.03 SEK); Q4 EPS: 0.01 SEK (Q4 2023: -0.02 SEK).

• Cash flow from operations for 2024: 3.2 MSEK (2023: 5.3 MSEK); cash at year-end: 2.6 MSEK (2023: 3.2 MSEK).

Outlook and guidance

• Updated business plan for 2025 focuses on accelerating sales and brand awareness to drive growth.

• Anticipates strong growth in the US, France, and UK, supported by regulatory trends and increased awareness.

• Expects continued expansion in recycling and healthcare segments, with a robust order book for 2025.